BAY-876

12/14/2021 - "The subcutaneous tumor models were established to determine the drug efficacy of BAY-876. "
12/31/2018 - "We herein took advantage of BAY-876 and molecular approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis. "
04/15/2023 - "The orally bioavailable selective GLUT1 inhibitor BAY-876 was developed primarily as an anti-tumor drug. "
12/14/2021 - "Tumor xenograft models further validated that BAY-876 could effectively suppress the in vivo growth of TRIM38low/- BLCA. "
01/01/2021 - "A series of HCC tumor models were established to determine not only the sustained release of microcrystalline BAY-876, but also its long-acting antitumor activity. "

01/01/2022 - "Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells."

05/01/2023 - "In vitro studies showed that GAS could also protect phenylephrine-induced cardiomyocyte hypertrophy, and these effects were attenuated by BAY-876, and increased by insulin. "

05/05/2021 - "Moreover, we conclude that BAY-876 can be a strong candidate for development of a new effective anticancer agent against breast cancer."
01/01/2022 - "MDA-MB-231 breast cancer and HPAFII pancreatic cancer cell lines tolerated the SNAT2 inhibitor up to a concentration of 100 µM but in combination with tolerable doses of the glucose transport inhibitor Bay-876, proliferative growth of both cell lines was halted. "

01/01/2022 - "DBI-1 and the GLUT1 inhibitor, BAY-876, synergistically inhibit colorectal cancer cell growth in vitro and in vivo. "